scholarly journals Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment

2019 ◽  
Vol 85 (6) ◽  
pp. 1239-1246 ◽  
Author(s):  
Muhammad Wasif Saif ◽  
Lee Rosen ◽  
Michelle A. Rudek ◽  
Weijing Sun ◽  
Dale R. Shepard ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Open-Label Study of the Safety and Pharmacokinetics of Solifenacin in Subjects With Hepatic Impairment

2006 ◽  
Vol 102 (4) ◽  
pp. 405-412 ◽  
Author(s):  
Mirjam Kuipers ◽  
Ronald Smulders ◽  
Walter Krauwinkel ◽  
Timothy Hoon
Keyword(s):  
Hepatic Impairment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2

2018 ◽  
Vol 118 (3) ◽  
pp. 344-352 ◽  
Author(s):  
Rastislav Bahleda ◽  
Andrea Varga ◽  
Yann Bergé ◽  
Jean-Charles Soria ◽  
David Schnell ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

Oncotarget ◽  
2014 ◽  
Vol 5 (22) ◽  
pp. 11154-11167 ◽  
Author(s):  
David S. Hong ◽  
Razelle Kurzrock ◽  
Marilyn Mulay ◽  
Erik Rasmussen ◽  
Benjamin M. Wu ◽  
...  
Keyword(s):  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Phase 1B

Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours

2011 ◽  
Vol 30 (5) ◽  
pp. 1962-1971 ◽  
Author(s):  
Tanja Trarbach ◽  
Beate Schultheis ◽  
Thomas C. Gauler ◽  
Vesile Schneider ◽  
Dirk Strumberg ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Src Inhibitor ◽  
Vegf Signalling

scholarly journals A phase I, open-label study of GSK1795091 administered in combination with immunotherapies in participants with advanced solid tumours (NCT03447314)

2019 ◽  
Vol 30 ◽  
pp. v192-v193
Author(s):  
A.R. Hansen ◽  
J. Strauss ◽  
J. Chaves ◽  
S.A. Piha-Paul ◽  
H. Park ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumours ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

scholarly journals Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”

2020 ◽  
Vol 65 (1) ◽  
pp. e02426-20
Author(s):  
Steven J. Kovacs ◽  
Lillian Ting ◽  
Jens Praestgaard ◽  
Gangadhar Sunkara ◽  
Haiying Sun ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
The Impact

scholarly journals Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.

1997 ◽  
Vol 41 (12) ◽  
pp. 2793-2796 ◽  
Author(s):  
H J Schaad ◽  
B G Petty ◽  
D M Grasela ◽  
B Christofalo ◽  
R Raymond ◽  
...  
Keyword(s):  
Hepatic Impairment ◽  
Matched Control ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Age And Gender ◽  
Open Label Study ◽  
Label Study ◽  
Dosing Interval ◽  
Immunodeficiency Virus ◽  
And Gender

This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease.

Sign in / Sign up

Export Citation Format

Share Document